Amgen Ruling Will Increase Section 337 Investigations
This decision, by a split panel, will have important effects on the frequency and scope of Section 337 investigations of alleged patent infringement involving FDA-regulated products.
The Court’s opinion in this case is significant for two reasons.
First, the Court determined that the safe harbor provided by 35 U.S.C. §...
To view the full article, register now.